# Long-term Safety and Efficacy of Nemolizumab With Moderate-to-severe Atopic Dermatitis

> **NCT03989206** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Galderma R&D** · enrollment: 1700 (estimated)

## Conditions studied

- Moderate-to-Severe Atopic Dermatitis

## Interventions

- **DRUG:** Nemolizumab

## Key facts

- **NCT ID:** NCT03989206
- **Lead sponsor:** Galderma R&D
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-12-30
- **Primary completion:** 2026-08-31
- **Final completion:** 2026-08-31
- **Target enrollment:** 1700 (ESTIMATED)
- **Last updated:** 2024-10-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03989206

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03989206, "Long-term Safety and Efficacy of Nemolizumab With Moderate-to-severe Atopic Dermatitis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03989206. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*